SHP099

製品コードS6388 バッチS638802

印刷

化学情報

Synonyms

N/A

Storage
(From the date of receipt)

3 years -20°C powder

化学式

C₁₆H₁₉Cl₂N₅

分子量

352.26

CAS No.

1801747-42-1

Solubility (25°C)*

体外

DMSO

70 mg/mL (198.71 mM)

Water

Insoluble

Ethanol

Insoluble

体内（毎回新しく調製した物を用意してください）

Homogeneous suspension

CMC-NA

≥5mg/ml

Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液（一定の濃度）を調合する

生物活性

製品説明	SHP099 is a highly potent, selective and orally bioavailable small-molecule SHP2 inhibitor with an IC50 value of 71 nM and shows no activity against SHP1.
in vitro	SHP099 is a highly potent, selective and orally bioavailable small-molecule SHP2 inhibitor with an IC50 value of 71 nM

プロトコル(参考用のみ)

細胞アッセイ	細胞株	Cell-free assays
	濃度	71 nM
	反応時間
	実験の流れ
動物実験	動物モデル	Mice
	投薬量	5 mg/kg
	投与方法	p.o.

参考

https://pubmed.ncbi.nlm.nih.gov/27347692/
https://pubmed.ncbi.nlm.nih.gov/27347692/

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

Intratumor heterogeneity in KRAS signaling shapes treatment resistance [ iScience, 2025, 28(2):111662]	PubMed: 39898020
A Hotspot Phosphorylation Site on SHP2 Drives Oncoprotein Activation and Drug Resistance [ bioRxiv, 2025, 2025.06.11.659120]	PubMed: 40667115
Tyrosine phosphatase SHP2 aggravates tumor progression and glycolysis by dephosphorylating PKM2 in gastric cancer [ MedComm (2020), 2024, 5(4):e527]	PubMed: 38576457
YAP/TAZ mediates resistance to KRAS inhibitors through inhibiting proapoptosis and activating the SLC7A5/mTOR axis [ JCI Insight, 2024, 9(24)e178535]	PubMed: 39704172
SHP2 inhibitors maintain TGFβ signalling through SMURF2 inhibition [ NPJ Precis Oncol, 2023, 7(1):136]	PubMed: 38102334
Elucidating the direct effects of the novel HDAC inhibitor bocodepsin (OKI-179) on T cells to rationally design regimens for combining with immunotherapy [ Front Immunol, 2023, 14:1260545]	PubMed: 37744352
Elucidating the direct effects of the novel HDAC inhibitor bocodepsin (OKI-179) on T cells to rationally design regimens for combining with immunotherapy [ Front Immunol, 2023, 14:1260545]	PubMed: 37744352
Protein Tyrosine Phosphatase Non-Receptor 11 (PTPN11/Shp2) as a Driver Oncogene and a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC) [ Int J Mol Sci, 2023, 24(13)10545]	PubMed: 37445722
Protein Tyrosine Phosphatase Non-Receptor 11 (PTPN11/Shp2) as a Driver Oncogene and a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC) [ Int J Mol Sci, 2023, 24(13)10545]	PubMed: 37445722
Early Combined SHP2 Targeting Reverses the Therapeutic Resistance of Vemurafenib in Thyroid Cancer [ J Cancer, 2023, 14(9):1592-1604]	PubMed: 37325052

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。